Genuine Virgin Aloe Corp dba Triderma - 679744 - 07/01/2024
正文 · 中文译文
警告信 Genuine Virgin Aloe Corp(以Triderma名义经营) MARCS-CMS 679744 — 2024年7月1日 更多警告信 警告信 关于警告信和关闭信 送达方式: 通过电子邮件确认送达 产品: 药品 收件人: 收件人姓名 Gloria J. Vanderlaan女士 收件人职务 首席执行官 Genuine Virgin Aloe Corp(以Triderma名义经营) 1395 N. Manassero Street 阿纳海姆,加利福尼亚州 92807 美国 签发办公室: 药品质量运营四部 美国 警告信 2024年7月1日 尊敬的Vanderlaan女士: 美国食品药品监督管理局(FDA)于2024年1月17日至29日检查了您的药品生产设施,即Genuine Virgin Aloe Corp(以Triderma名义经营),FEI 3008235829,地址为加利福尼亚州阿纳海姆市北Manassero街1395号。 本警告信概述了成品药品现行良好生产规范(CGMP)法规的重大违规行为。参见《美国联邦法规》第21篇第210和211部分(21 CFR第210和211部分)。 由于您的生产、加工、包装或储存的方法、设施或控制不符合CGMP,您的药品属于《联邦食品、药品和化妆品法案》(FD&C法案)第501(a)(2)(B)条、21 U.S.C. 351(a)(2)(B)所指的掺假产品。 我们详细审查了您2024年2月19日对我们FDA 483表的回复。 在检查期间,我们的调查员观察到具体违规行为,包括但不限于以下内容。 1. 贵公司未能对每种组分的样品进行鉴别检验,并确认其符合所有适当的书面质量标准中的纯度、效力和质量要求。贵公司还未能以适当间隔验证和建立组分供应商检验分析的可靠性(21 CFR 211.84(d)(1) 和 211.84(d)(2))。 贵公司生产非处方(OTC)药品,例如用于湿疹和糖尿病患者的皮肤保护霜。贵公司未能对用于生产OTC药品的进厂原料(如salicylic acid、allantoin和colloidal oatmeal)进行充分的鉴别检验。此外,贵公司依赖供应商的分析证书(COA),而未以适当间隔建立组分供应商检验分析的可靠性。 贵公司亦未对每批来料中二甘醇(DEG)或乙二醇(EG)污染高风险的每种组分进行充分检测。这些检测包括但不限于对贵公司用于生产药品的甘油进行检测以确定其适当鉴别。甘油及其他高风险药品组分的鉴别检测1包括美国药典(USP)中的限度检查,以确保该组分符合DEG或EG水平的相关安全限度。由于贵公司未使用可检出这些有害杂质的USP鉴别试验对每批甘油的每次来货进行鉴别检测,贵公司未能确保这些组分可用于贵公司药品的生产。 使用被DEG或EG污染的原料已在全球范围内导致多起致死性中毒事件。参见FDA指南文件《甘油、丙二醇、麦芽糖醇溶液、氢化淀粉水解物、山梨醇溶液及其他高风险药品组分的二甘醇和乙二醇检测》,以帮助贵公司在生产含有DEG或EG污染高风险组分的药品时符合CGMP要求,网址为https://www.fda.gov/media/167974/download。 在贵公司的回复中,贵公司承诺执行“COA中规定的所需物理、分析和微生物检测,以验证产品符合约定质量标准”。 你们的回复不充分,因为你们未能提供足够详细信息,说明将如何确保对每批进厂原料至少进行一项身份检测,以及如何以适当间隔确立你们组分供应商COA的可靠性。你们也没有说明将如何评估你们已分销且在有效期内的药品中所用组分的质量。 针对本函,请提供: 承诺在自本函日期起30个日历日内,提供用于药品生产的所有高风险药物组分批次留样的二甘醇(DEG)和乙二醇(EG)检测结果。或者,如果某组分批次无留样,则对所有相关成品药品批次进行留样检测,以确定是否存在DEG和EG。 对在有效期内且含有任何存在DEG或EG污染风险成分(包括但不限于甘油)的药品进行全面风险评估。采取及时且适当的措施,确定所有可能含有DEG或EG的组分批次及相关药品的安全性,包括对任何受污染批次进行客户通知和产品召回。确定额外的适当纠正措施和预防措施(CAPA),以保障未来供应链安全,包括但不限于确保所有进厂原料批次来自完全合格的生产商且不含不安全杂质。在你们对本函的回复中详细说明这些措施。 描述你将如何检测每个组分批次,以确认其符合关于鉴别、强度、质量和纯度的所有适当质量标准。如果你打算接受供应商COA中的任何结果,而不对每个组分批次进行强度、质量和纯度检测,请说明你将如何通过初始验证以及定期再验证来稳健地确立供应商结果的可靠性。此外,还应包括一项承诺,即始终对每个 incoming 组分批次至少进行一项特异性鉴别检测。对于甘油、丙二醇和某些其他高风险组分,我们指出,这包括执行USP各论中的A、B和C部分。 你用于检测和放行每个incoming组分批次以供生产使用的化学和微生物质量控制标准。 对你的物料系统进行全面、独立的审查,以确定组分、容器和密封件的所有供应商是否各自合格,以及物料是否被分配了适当的有效期或复验期。该审查还应确定incoming物料控制是否足以防止使用不合格的组分、容器和密封件。 对你用于对incoming组分和你生产的成品制剂进行检测的合同设施进行资质认定和监督的program摘要。 2. 你公司未能建立旨在确保所生产药品具有其声称或表示所具备的鉴别、含量、质量和纯度的生产与过程控制的书面程序(21 CFR 211.100(a))。 你公司未能验证用于生产药品的过程。此外,你公司无法提供证据证明你公司已对所有生产设备进行了确认。 在你公司的回复中,你公司声明将进行设备确认,并验证你公司的生产工艺。 你公司的回复不充分,因为你公司未承诺确保在产品分销之前完成前瞻性验证研究,也未包括对采用未经确认的过程生产的已上市药品的风险评估。 没有充分的过程验证,你公司缺乏基本保证,无法确保能够持续交付符合标准的产品。参见FDA指南文件《过程验证:一般原则与实践》,了解FDA认为过程验证适当要素的一般原则和方法,网址为https://www.fda.gov/media/71021/download。 针对本函,请提供: 你公司验证计划的详细摘要,该计划用于确保在整个产品生命周期内保持受控状态,以及相关程序。描述你公司的过程性能确认(PPQ)计划,以及对批内和批间变异的持续监测,以确保维持持续受控状态。 为您每个上市药品执行适当工艺性能确认(PPQ)的时间表。包括您的工艺性能方案,以及设备和设施确认的书面程序。 对使用验证不充分工艺生产的流通药品的风险评估。 提供详细方案,用于设计、验证、维护、控制和监测您的每个生产工艺,其中包括对批内和批间变异进行警惕性监测,以确保处于持续受控状态。此外,包括您的设备和设施确认方案。 3. 贵公司未能建立适当的书面检测方案,用以评估药品的稳定性特征,并使用稳定性检测结果确定适当的贮存条件和有效期。(21 CFR 211.166(a))。 贵公司未能建立适当的稳定性方案,并为您生产的药品确定适当的有效期。您为许多药品指定了三年有效期,但未能提供数据证明其化学和物理属性在所指定有效期内将保持可接受。 在你的回复中,你表示会将药品置于加速稳定性研究中以签发暂定有效期,并将(b)(4)个商业批次的药品置于长期稳定性研究中以确认暂定有效期。你的回复未能说明你是否会在稳定性方案中使用经过验证的稳定性指示方法。 针对本函,请提供以下内容: 一份全面、独立的评估及纠正和预防措施(CAPA)计划,以确保你的稳定性方案的充分性。你整改后的方案应包括但不限于: o 稳定性指示方法。 o 每种药品在其上市容器密闭系统中的地位于批准分销前进行的稳定性研究。 o 一项持续进行的方案,每年将每种药品的代表性批次加入该方案,以确定有效期声明是否仍然有效。 o 详细定义每个检测点(时间点)需检测的具体属性。 o 描述你整改后稳定性方案中上述及其他要素的所有规程。 4. 你的公司未能建立适当的质量部门,且适用于质量控制部门的职责和规程未以书面形式制定并完全遵守(21 CFR 211.22(a) 和 (d))。 你的质量部门(QU)未能对你的CGMP记录提供适当的监督。例如,你的银屑病控制霜(Psoriasis Control Cream)批记录,批号(b)(4),包含不完整的信息。此外,你的QU未能遵循你们进行年度产品审核的规程。 在你们的回复中,你们表示已为批生产记录审核和年度产品回顾建立了新程序。你们的回复不充分,因为你们未评估是否审核了其他生产记录中缺失的信息,也未评估批记录中不完整或缺失的信息是否影响了已销售的药品。 本函中的重大发现表明,贵公司未按照CGMP运行有效的质量体系。除对生产操作缺乏有效的管理监督外,我们发现你们的质量部门(QU)未能行使适当职权和/或未充分履行其职责。高管层应立即全面评估贵公司的全球生产运营,以确保你们的系统、流程和产品符合FDA的要求。 有关实施质量体系和风险管理方法以满足CGMP法规21 CFR第210和211部分要求的帮助,请参阅FDA的指南文件《药品CGMP法规的质量体系方法》,网址为https://www.fda.gov/media/71023/download。 针对本函,请提供以下内容: 一份全面的评估和整改计划,以确保你们的QU获得有效运作所需的职权和资源。该评估还应包括但不限于: o 确定贵公司所使用的程序是否稳健且适当。 o 在整个运营过程中为质量部门(QU)监督做出安排,以评估对适当规范的遵守情况。 o 在质量部门做出处置决定之前,对每一批及其相关信息进行完整和最终的审核。 o 对调查进行监督和批准,并履行所有其他质量部门职责,以确保所有产品的鉴别、规格、质量和纯度。 建议聘请CGMP顾问 根据我们在贵公司发现的违规行为的性质,您应聘请符合21 CFR 211.34规定的合格顾问来评估您的运营,并协助贵公司满足CGMP要求。该合格顾问还应针对整个运营进行全面的六系统CGMP合规审计,并在您寻求解决贵公司对FDA的合规状态之前,评估CAPA的完成情况和有效性。您使用顾问并不免除贵公司遵守CGMP的义务。贵公司的执行管理层仍负责解决所有缺陷和系统性缺陷,以确保持续的CGMP合规。 结论 本函中引用的违规行为并非旨在成为您设施中存在的所有违规行为的详尽清单。您有责任调查和确定任何违规行为的原因,并防止其再次发生或其他违规行为的发生。 请及时纠正任何违规行为。未能及时、充分地处理此事项可能导致监管或法律行动,恕不另行通知,包括但不限于查封和禁令。未解决的违规行为还可能阻止其他联邦机构授予合同。未能处理违规行为还可能导致FDA扣发出口证书。在 any 违规行为完全解决且我们确认贵公司符合CGMP之前,FDA可能暂缓批准将贵公司列为药品生产商的新申请或补充申请。我们可能重新检查,以核实贵公司已完成纠正措施以处理任何违规行为。 本函告知贵公司我们的发现,并为贵公司提供处理上述缺陷的机会。收到本函后,请在15个工作日内以书面形式回复本办公室。请说明贵公司已采取哪些措施处理任何违规行为并防止其再次发生。作为对本函的回复,贵公司可提供额外信息供我们考虑,以便我们继续评估贵公司的活动和做法。如果贵公司无法在15个工作日内完成纠正措施,请说明延迟原因及完成时间表。 请将电子回复发送至 ORAPHARM4_Responses@FDA.HHS.GOV,或将回复邮寄至: CDR Steven E. Porter, Jr. Director, Division of Pharmaceutical Quality Operations IV U.S. Food & Drug Administration 19701 Fairchild Road Irvine, California 92612-2506 请在回复中注明唯一标识符:CMS 679744。 如对发布的信息有任何疑问,请联系合规官Yumi Hiramine,邮箱Yumi.Hiramine@fda.hhs.gov,电话(818) 226-1839。 此致, /S/ CDR Steven E. Porter, Jr. 药品质量运营四司司长 __________________ 1 与其他药品成分相比,二甘醇(DEG)或乙二醇(EG)污染风险较高的成分。 内容更新日期: 07/23/2024 受监管产品 药品
正文 · 英文原文
WARNING LETTER Genuine Virgin Aloe Corp dba Triderma MARCS-CMS 679744 — July 01, 2024 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA EMAIL CONFIRMED DELIVERY Product: Drugs Recipient: Recipient Name Ms. Gloria J. Vanderlaan Recipient Title Chief Executive Officer Genuine Virgin Aloe Corp dba Triderma 1395 N. Manassero Street Anaheim, CA 92807 United States Issuing Office: Division of Pharmaceutical Quality Operations IV United States WARNING LETTER July 1, 2024 Dear Ms. Vanderlaan: The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Genuine Virgin Aloe Corp, dba Triderma, FEI 3008235829, at 1395 North Manassero Street, Anaheim, CA, from January 17 to 29, 2024. This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211). Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B). We reviewed your February 19, 2024, response to our Form FDA 483 in detail. During our inspection, our investigator observed specific violations including, but not limited to, the following. 1. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality. Your firm also failed to validate and establish the reliability of your component supplier's test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)). Your firm manufactures over-the-counter (OTC) drug products such as skin protectant creams for eczema and diabetics. You failed to conduct adequate identity testing on incoming raw materials such as salicylic acid, allantoin, and colloidal oatmeal used in the manufacture of your OTC drug products. Furthermore, you relied on your suppliers’ certificate of analyses (COA) without establishing the reliability of your component suppliers’ test analyses at appropriate intervals. Your firm also failed to adequately test each shipment of each lot of incoming components at high risk of diethylene glycol (DEG) or ethylene glycol (EG) contamination. These include, but are not limited to, testing of glycerin, you use in manufacturing drug products to determine its appropriate identity. Identity testing of glycerin, along with other high-risk drug components,1 include a limit test in the United States Pharmacopeia (USP) to ensure that the component meets the relevant safety limits for levels of DEG or EG. Because you did not perform identity testing on each shipment of each glycerin lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of these components for use in the manufacture of your drug products. The use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See the FDA’s guidance document Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for DEG or EG contamination at https://www.fda.gov/media/167974/download. In your response, you commit to performing “required physical, analytical, and microbial tests specified in the COA to verify the product’s compliance with the agreed-upon specifications.” Your response is inadequate because you failed to provide sufficient details regarding how you will ensure that at least one identity test for each lot of incoming raw materials is performed, and how you establish the reliability of your component suppliers’ COAs at appropriate intervals. You also did not address how you will assess the quality of your components used in your distributed drug products that are within expiry. In response to this letter, provide: A commitment to provide DEG and EG test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of DEG and EG. A full risk assessment for drug products that are within expiry which contain any ingredient at risk for DEG or EG contamination (including, but not limited to, glycerin). Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain DEG or EG, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate corrective action and preventive action (CAPA) that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter. A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your suppliers’ COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your suppliers’ results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of glycerin, propylene glycol, and certain additional high-risk components we note that this includes the performance of parts A, B, and C of the USP monograph. The chemical and microbiological quality control specifications you use to test and release each incoming lot of component for use in manufacturing. A comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures. A summary of your program for qualifying and overseeing contract facilities that test the incoming components and finished drug products you manufacture. 2. Your firm failed to establish written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)). Your firm failed to validate the processes used to manufacture your drug products. In addition, you could not provide evidence that you have qualified all of your manufacturing equipment. In your response you state that you will conduct equipment qualification, as well as validate your manufacturing processes. Your response is inadequate because you did not commit to ensuring prospective validation studies are completed prior to the distribution of your products, nor did you include a risk assessment for marketed drug products manufactured by unvalidated processes. Without adequate process validation, your firm lacks basic assurance that you can consistently deliver products that meet specifications. See the FDA’s guidance document Process Validation: General Principles and Practices for general principles and approaches that the FDA considers appropriate elements of process validation at, https://www.fda.gov/media/71021/download. In response to this letter, provide: A detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification (PPQ), and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control. A timeline for performing appropriate PPQ for each of your marketed drug products. Include your process performance protocol(s), and written procedures for qualification of equipment and facilities. A risk assessment for the distributed drug product produced using inadequately validated process. Provide a detailed program for designing, validating, maintaining, controlling, and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility. 3. Your firm failed to establish an adequate written testing program designed to assess the stability characteristics of drug products and to use results of stability testing to determine appropriate storage conditions and expiration dates. (21 CFR 211.166(a)). Your firm failed to establish an adequate stability program and determine appropriate expiration dates for the drug products that you manufacture. You assigned a three-year expiry period to many of your drug products but failed to provide data to demonstrate that their chemical and physical attributes will remain acceptable throughout the expiry period assigned. In your response, you state that you would place drug products on accelerated stability studies to issue tentative expiration dates, and place (b)(4) commercial batches in long term stability studies to confirm tentative expiration dates. Your response fails to indicate whether you are going to use validated stability indicating methods in your stability program. In response to this letter, provide the following: A comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to: o Stability indicating methods. o Stability studies for each drug product in its marketed container-closure system before distribution is permitted. o An ongoing program in which representative batches of each drug product are added each year to the program to determine if the shelf-life claim remains valid. o Detailed definition of the specific attributes to be tested at each station (timepoint) o All procedures that describe these and other elements of your remediated stability program. 4. Your firm failed to establish an adequate quality unit and the responsibilities and procedures applicable to the quality control unit are not in writing and fully followed (21 CFR 211.22(a) and (d)). Your quality unit (QU) failed to provide adequate oversight of your CGMP records. For example, your batch record for Psoriasis Control Cream, lot (b)(4), contained incomplete information. Additionally, your QU failed to follow your procedures for conducting annual product reviews. In your response, you indicate you have created new procedures for batch production record review and annual product reviews. Your response is inadequate because you do not assess whether you reviewed other production records for missing information and whether the incomplete or missing information in the batch records affected distributed drug products. Significant findings in this letter demonstrate that your firm does not operate an effective quality system in accordance with CGMP. In addition to the lack of effective management oversight of your production operations, we found your QU is not enabled to exercise proper authority and/or has insufficiently implemented its responsibilities. Executive management should immediately and comprehensively assess your company’s global manufacturing operations to ensure that your systems, processes, and products conform to the FDA requirements. See the FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https://www.fda.gov/media/71023/download. In response to this letter, provide the following: A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to: o A determination of whether procedures used by your firm are robust and appropriate. o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices. o A complete and final review of each batch and its related information before the QU disposition decision. o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products. CGMP Consultant Recommended Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your CAPAs before you pursue resolution of your firm’s compliance status with the FDA. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance. Conclusion The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure, and injunction. Unresolved violations may also prevent other federal agencies from awarding contracts. Failure to address violations may also cause the FDA to withhold issuance of Export Certificates. The FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations. This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion. Please send your electronic reply to ORAPHARM4_Responses@FDA.HHS.GOV or mail your reply to: CDR Steven E. Porter, Jr. Director, Division of Pharmaceutical Quality Operations IV U.S. Food & Drug Administration 19701 Fairchild Road Irvine, California 92612-2506 Please identify your responses with the unique identifier: CMS 679744. If there is any question about the released information, please contact Yumi Hiramine, Compliance Officer at Yumi.Hiramine@fda.hhs.gov, or at (818) 226-1839. Sincerely, /S/ CDR Steven E. Porter, Jr. Director, Division of Pharmaceutical Quality Operations IV __________________ 1 Components with higher risk of DEG or EG contamination compared to other drug components. Content current as of: 07/23/2024 Regulated Product(s) Drugs